The role of FXR in the regulation of hepatic triglyceride and glucose homeostasis [6,55,56] has been well described and several FXR agonist drugs have been developed for treating dyslipidemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and to improve liver functions [6]. Here, NR1H4 is linked to metabolic syndrome.